Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Outlicenses Two CCR5 Antagonists To Newly Formed Tobira

This article was originally published in PharmAsia News

Executive Summary

A new chemokine receptor 5 antagonist candidate licensed this week to Tobira Therapeutics by Takeda could provide a dosing advantage over other CCR5 antagonists in development, such as Pfizer's maraviroc and Schering-Plough's vicriviroc, according to Tobira CEO James Sapirstein
Advertisement

Related Content

Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists
Pfizer’s Maraviroc Deemed “Approvable” By FDA
Advertisement
UsernamePublicRestriction

Register

SC066490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel